ABI-6250

Phase 2Small molecule

AAssembly Biosciences

ABI-6250 is one of 2 small molecule programs targeting Chronic Hepatitis D Infection. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Hepatitis D InfectionNot yet recruiting

Chronic Hepatitis D InfectionPhase 2

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Chronic Hepatitis D Infection

#DrugCompanyPhaseTrials

Brelovitug

MMirum Pharmaceuticals, Inc.

Phase 3

2 2

ABI-6250

AAssembly Biosciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Not yet recruiting

Chronic Hepatitis D Infection

NCT07762027

Clinical

Trials by Indication[1]

Tics1 trial

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ABI-6250 in Healthy Participants

Completed·AAssembly Biosciences·Phase 1·NCT06740474·40 enrolled

Chronic Hepatitis D Infection1 trial

A Phase 2, Multicenter, Open Label, Parallel-Group Study of the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection

Not yet recruiting·AAssembly Biosciences·Phase 2·NCT07762027·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ABI-6250. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ABI-6250 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ABI-6250. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assembly Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAssembly Biosciences

ABI-6250

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Tics1 trial

Chronic Hepatitis D Infection1 trial

References

Drug Info

Quick Facts

Related News